LogicBio Therapeutics develops gene therapy vectors for previously incurable genetic and infectious diseases, including hemophilia, HIV/AIDS, and methylmalonic acidemia. The company's proprietary technology is based on the nonpathogenic adeno-associated viral vector. The technology may offer improved efficiency and safety, and it is well suited for the treatment of both children and adults.
Cumulative Funding Raised Over Time ($)
Employees Over Time
LogicBio Therapeutics Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Oct 21, 2018
www.calcalistech.com
LogicBio Therapeutics Underperforms with $70 Million Nasdaq IPO
#Public Trading #Investment
Jun 28, 2017
www.fiercebiotech.com
Arix leads $45M series B for gene therapy biotech LogicBio
undefined
Jun 28, 2017
www.globes.co.il
Gene therapy co LogicBio raises $50m
#Investment #Expand
Jan 21, 2016
medcitynews.com
OrbiMed-backed LogicBio raises $4M for hemophilia gene therapy